Which group of Stage III MSI-H colon cancer patients can be excluded from receiving adjuvant chemotherapy?   

10% to 15% of patients with early-stage, and 4% of patients with metastatic colorectal cancer (CRC) test positive for dMMR. In stage II-III colon cancers, MSI-H/dMMR status is predictive of resistance to 5-fluorouracil as monotherapy, (Sargent et al., PMID 20498393) such that the addition of ox...